<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, April 23, 2018 (HealthDay News) — A smartphone app is associated with improved short-term adherence to a cutaneous foam treatment for psoriasis, according to a study published online April 14 in the British Journal of Dermatology<\/i>.<\/p>\n
Mathias Tiedemann Svendsen, M.D., from Odense University Hospital in Denmark, and colleagues randomized 122 patients who were receiving once-daily medication (calcipotriol\/betamethasone dipropionate [Cal\/BD] cutaneous foam) to either no app (66 patients) or an app intervention (68 patients).<\/p>\n
The researchers found that at week four, more patients in the intervention group were adherent to Cal\/BD cutaneous foam versus patients in the non-intervention group (65 versus 38 percent: P = 0.004). The intervention group also showed a greater reduction in psoriasis severity, as measured by the Lattice System Physician’s Global Assessment, versus the non-intervention group at week four (P = 0.047). While not reaching statistical significance, a similar effect was seen at weeks eight and 26.<\/p>\n
“The app significantly improved adherence rates and reduced psoriasis severity in the short-term,” the authors write.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including LEO Pharma, which supported the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n